Optimal seizure management in brain tumor patients

Current Neurology and Neuroscience Reports

Volumn 5, Issue 3, 2005, Pages 207-213

  van Breeman, Melanie S M ^b   Vecht, Charles J ^a  

^a Loc Westeinde   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBAMAZEPINE; CARMUSTINE; CISPLATIN; CLOBAZAM; CORTICOSTEROID; CYTOCHROME P450; DOXORUBICIN; ETIRACETAM; ETOPOSIDE; FELBAMATE; FLUOROURACIL; GABAPENTIN; GLYCOPROTEIN P; LAMOTRIGINE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; NITROSOUREA; PHENOBARBITAL; PHENYTOIN; TAXANE DERIVATIVE; TENIPOSIDE; TOPIRAMATE; VALPROIC ACID; VINCA ALKALOID;

ASTROCYTOMA; BRAIN CANCER; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG INHIBITION; DRUG METABOLISM; EPILEPSY; GLIOBLASTOMA; GLIOMA; HUMAN; INCIDENCE; MEDICAL DECISION MAKING; MENINGIOMA; NEUROSURGERY; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT SELECTION; PROPHYLAXIS; RETROSPECTIVE STUDY; REVIEW; SYMPTOM; TREATMENT OUTCOME; TUMOR LOCALIZATION;

EID: 21044457839     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-005-0048-6     Document Type: Review

References (46)

1. Herman ST: Epilepsy after brain insult. Neurology 2002, 599(Suppl 5):S21-S26.
2. Hauser WA, Annegers JF, Kurland LT: Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1988, 34:453-468.
3. Morris HH, Estes ML: Brain tumors and epilepsy. In The Treatment of Epilepsies. Principles & Practice. Edited by Wyllie E. Cleveland: Lippincott Williams & Wilkins; 2001: 615-626.
4. Cascino GD: Epilepsy and brain tumors: implications for treatment. Epilepsia 1990, 31(Suppl 3):S37-S44.
5. Mahaley MS, Dudka L: The role of anticovulsant medications in the management of patients with anaplastic gliomas. Surg Neurol 1981, 16:399-401.
6. Fish DR: How do tumors cause epilepsy? In The Epilepsies. Etiologies and Prevention. Edited by Kotagal P, Lüders HO. Cleveland: Academic Press; 1999:301-314.
7. Morrell F, Toledo-Morell L: Secondary epileptogenesis and brain tumors. In The Epilepsies. Etiologies and Prevention. Edited by Kotagal P, Lüders HO. Cleveland: Academic Press; 1999:357-363.
8. Villemure JG, De Tribolet N: Epilepsy in patients with central nervous system tumors. Curr Opin Neurol 1996, 9:424-428.
9. Wolf HK, Roos D, Blümcke I, et al.: Perilesional neurochemical changes in focal epilepsies. Acta Neuropathologica 1996, 91:376-384.
10. Gilmore R, Morris H, Van Ness PC, et al.: Mirror focus: function of seizure frequency and influence on outcome after surgery. Epilepsia 1994, 35:258-263.
11. Bateman DE, Hardy JA, McDermott JR, et al.: Amino acid transmitter levels in gliomas and their relationship to the incidence of epilepsy. Neurol Res 1988, 10:112-114.
12. Schaller B, Rüegg S: Brain tumor and seizures: pathophysiology and its implications for treatment revisited. Epilepsia 2003, 44:1223-1232.
13. Aronica E, Gorter JA, Jansen GH, et al.: Expression of connexion 43 and connexion 32 gap-junction proteins in epilepsy-associated brain tumors and in the perilesional epileptic cortex. Acta Neuropathol 2001, 101:449-459.
14. Bourekas EC, Perl J: Imaging tumors in epilepsy. In The Epilepsies. Etiologies and Prevention. Edited by Kotagal P, Lüders HO. Cleveland: Academic Press; 1999:315-335.
15. Glantz MJ, Cole BF, Forsyth PA, et al.: Practice parameter: anti-convulsant prophylaxis in patients with newly diagnosed brain tumors: report of quality standards subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886-1893.
16. Morris HH, Estes ML, Gilmore R, et al.: Chronic intractable epilepsy as the only symptom of primary brain tumor. Epilepsia 1993, 34:1038-1043.
17. Wen PY, Marks PW: Medical management of patients with brain tumors. Oncology 2002, 14:299-307.
18. Moots PL, Maciunas RJ, Eisert DR, et al.: The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995, 52:717-724.
19. Devinsky O: Patients with refractory seizures. N Engl J Med 1999, 20:1565-1570.
20. Sisodiya SM, Lin WR, Harding BN, et al.: Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002, 125:22-31.
21. Löscher W, Poitschka H: Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exper Ther 2002, 301:7-14.
22. Rogawski MA: Does P-glycoprotein play a role in pharmacoresistance to antiepileptic drugs? Epilepsy Behav 2002, 3:493-495.
23. Siddiqui A, Kerb R, Weale ME, et al.: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003, 348:1442-1448.
24. Tan B, Piwnica-Worms D, Ratner L: Multidrug resistance transporters and modulation. Curr Opin Oncol 2000, 12:450-458.
25. Goldman B: Multidrug resistance: can new drugs help chemotherapy score against cancer? J Natl Cancer Inst 2003, 95:255-257.
26. Britton JW, Cascino GD, Sharbrough FW, Kelly PJ: Low-grade glial neoplasms and intractable partial epilepsy: efficacy of surgical treatment. Epilespia 1994, 35:1130-1135.
27. Stephen LJ, Kwan P, Brodie MJ: Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment? Epilepsia 2001, 42:357-362.
28. Wagner GL, Wilms EB, Van Donselaar CA, Vecht CJ: Levetiracetam: the preliminary experience in patients with primary brain tumours. Seizure 2003, 12:585-586.
29. Siddiqui F, Wen P, Dworetzky B, et al.: Use of levetiracetam in patients with brain tumors. Epilepsia 2002, 43(Suppl 7):297.
30. Perry JR, Sawka C: Add-on Gabapentin for refractory seizures in patients with brain tumours. Can J Neurol Sci 1996, 23:128-131.
31. Franceshetti S, Binelli S, Casazza M, et al.: Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumors. Acta Neurochirurg 1990, 103:47-51.
32. North JB, Penhall RK, Hanieh A, et al.: Phenytoin and post-operative epilepsy. J Neurosurg 1983, 58:672-677.
33. Shaw MDM: Post-operative epilepsy and the efficacy of anti-consulvant therapy. Acta Neurochirurg 1990, S50:55-57.
34. Cohen N, Strauss G, Lew R, et al.: Should prophylactic anticonsulvants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988, 6:1621-1624.
35. Taphoorn JB: Neurocognitive sequelae in the treatment of low-grade gliomas. Semin Oncol 2003, 30:45-48.
36. Rowan AJ, James RA: Reflections on the treatment of seizures in the elderly population. Neurology 1998, 51:S28-S33.
37. Baker AF, Dort RT: Drug interactions with the taxanes: clinical implications. Cancer Treat Rev 2001, 27:221-233.
38. Vecht CJ, Wagner L, Wilms EB: Interactions between antiepileptic and chemotherapeutic drugs. Lancet 2003, 2:404-409.
39. Grossman SA, Hochberg F, Fisher J, et al.: Increase 9-amino-camtothecin dose requirements in patients on anticonsulvants. Cancer Chenother Pharmacol 1998, 42:118-126.
40. Neef C, de Voogd-van der Straaten I: An interaction between cytostatic and anticonsvulsant drugs. Clin Pharmacol Ther 1998, 43:372-375.
41. Gilber PJ, Brodribb TR: Phenytoin and fluorouracil interaction. Ann Pharmacother 2001, 35:1367-1370.
42. Cascino GD: Surgical treatment for epilepsy. Epilepsy Res 2004, 60:179-186.
43. Zentner J, Hufnagel A, Wolf HK, et al.: Surgical treatment of neplasms associated with medically intractable epilepsy. Neurosurgery 1997, 41:378-386.
44. Morris HH, Matkovic Z, Estes ML, et al.: Ganglioglioma and intractable epilepsy: clinical and neurophysiologic features and predictors of outcome after surgery. Epilepsia 1998, 39:307-313.
45. Luyken C, Blümcke I, Fimmers R, et al.: The spectrum of epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia 2003, 44:822-830.
46. Brainer-Lima PT, Rao S, Cukiert A, et al.: surgical treatment of refractory epilepsy associated with space occupying lesions. Arq Neuropsiquiatr 1996, 54:384-392.